Creating a New Future of Early Cancer Screening at Home, Bringing Precise Early Screening into Thousands of Households

——Linaxin Biotechnology successfully held a "Product Launch and New and Old Customer Appreciation Event"

January 18, 2022 is destined to become a milestone in the development history of Linaxin Biotechnology.

At 10 am on the same day, Suzhou Linaxin Biotechnology Co., Ltd. successfully held a "Product Launch and New and Old Customer Appreciation Meeting" at Kunshan Huaqiao International Innovation Port. The meeting invited relevant leaders and guests from Kunshan Huaqiao Science and Technology Bureau, Kunshan Yinqiao Group, Nantong Center for Disease Control and Prevention, and China Medical Supplies Association, as well as professors, PhDs, and company partners from multiple universities to participate in the event.

Three early cancer screening and self testing products focusing on the home digestive system were released at the event site, namely the multi gene mutation combined with DNA methylation early screening product for colorectal cancer, "Li Changsheng" ®”、 Home digestive tract occult blood self-test devices "Changle XinTM" and "Changwei LeTM". Core product "Li Changsheng ®”， It comprehensively evaluates the risk of colorectal cancer by detecting DNA mutations in fecal exfoliated cells in the human intestine. There are 6 targets and over 30 loci, achieving home, non-invasive, painless prevention of colorectal cancer risk 5-7 years in advance; The home warning self-test devices "Changle XinTM" and "Changwei LeTM" do not require dietary control and achieve home self-test. The results can be viewed in 20 seconds, truly realizing prevention and testing without leaving home.

The release of three products proves the R&D capability and sustainable development potential of Linaxin Biotechnology based on the molecular detection platform. The strategic cooperation signed with the national OTC pharmacy channel on site also marks the broad prospects for the commercialization of the company's products.

At the press conference, Dr. Tan Shengwei, founder of Linaxin Biotechnology, collaborated with several professors and doctors from Southeast University, Nanjing University, Institute of Nanoscience and Technology of the Chinese Academy of Sciences, Nanjing University of Posts and Telecommunications, and Harvard University to launch a project for a "nanopore digestive tract cancer early screening product" based on fourth generation gene sequencing technology. This product can achieve decentralized, portable, low-cost, and rapid detection in the future, and precise early screening of cancer can be completed without the need for a laboratory. The fourth generation nanopore cancer early screening technology is precise, fast, and leak free. It can accurately analyze DNA without losing any useful structural and kinetic information, completely eliminating the elution process and PCR amplification process. Even if there is a site mutation, it can be accurately identified. The report issuance time has also been shortened from 5-7 days to 1-2 hours, allowing users to quickly obtain health information without leaving their homes.

The approval of this product demonstrates the strong technical reserves of Linaxin Biotechnology in the field of nanopore sequencing technology. In the future, achieving "one sample, one hour, several hundred yuan" cancer early screening will no longer be just a dream.

This is an era of innovation sweeping the globe, an era of technological elites writing history, and an era of early cancer screening outbreaks in the big health industry. At present, the country is vigorously supporting the development of health and medical services, advocating the establishment of a scientific and efficient system, encouraging innovation, producing high-end and innovative medical equipment products, enriching domestic medical resources, and accelerating the pace of import substitution.

Suzhou Linaxin Biotechnology Co., Ltd. was born in this context. The company was founded in 2019 and is located in Huaqiao International Innovation Port, Kunshan, China. It borders Shanghai to the east and Suzhou to the west, and is situated in the central part of the Yangtze River Delta, which is the most economically powerful region in China. The company is an advanced technology enterprise specializing in early screening of home cancer. It was jointly founded by leading talents, domestic and foreign biomedical PhDs, and gene sequencing scientists. The expert committee is composed of national Changjiang scholars, professors, and clinical experts from tumor hospitals.

Suzhou Linaxin Biotechnology has 15 independent intellectual property rights and its wholly-owned subsidiary, Linaxin Nuokang (Shandong) Biomedical Technology Co., Ltd., has passed the quality system certification of the Food and Drug Administration, obtained two national second-class medical device registration certificates, and obtained 6840 in vitro diagnostic and clinical testing device production licenses. It has a 3500 square meter GMP production base of 100000 and 10000 levels, five internationally advanced cancer early screening production lines, and an annual production capacity of up to 1 billion yuan. The Binzhou Medical Inspection Center, jointly built with Binzhou Xinyue Rehabilitation Hospital, has an annual inspection and measurement capacity of up to 500000 people. Currently, it has reached a strategic cooperation agreement of 40 million yuan with multiple strategic partners for the year 2022.

Linaxin Biotechnology, which integrates research and development, production, sales, and inspection, has reached a high level in various aspects such as production equipment, professional technical personnel, quality management system, and after-sales service capabilities in the industry.

Linaxin Biotechnology will take the mission of "screening one sample early, saving one life, benefiting one family, and improving people's health level", to break through the last mile of cancer early screening and safeguard the health of the people!

Only with foresight can there be a future, and only with vitality can there be value. We believe that Linaxin Biotechnology will take this product launch event as an opportunity to integrate resources from a global perspective, with advanced technology, high-quality products, excellent services, and extraordinary courage, and strive to achieve the great dream of a Healthy China by 2030!